Algernon Appoints Novotech As CRO for Phase 2 Coronavirus Ifenprodil Trial
UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, announced that it has chosen to appoint award winning Novotech as the... Read More
Algernon Announces Filing of U.S. FDA Pre-Ind Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use
UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, announced that it has filed its pre-IND (Investigational New Drug) meeting request... Read More
Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus
UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, announced that it is exploring the potential of using NP-120 (Ifenprodil) as... Read More
Algernon Signs Novotech Up for Midstage Respiratory Therapy Test
UF startup Algernon Pharmaceuticals has chosen contract research organization (CRO) Novotech to help run its phase 2 idiopathic pulmonary fibrosis and chronic... Read More
Algernon Pharmaceuticals Finding New Uses for Safe, Older Drugs
Christopher Moreau, CEO of UF startup Algernon Pharmaceuticals, Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, sat down with... Read More
Algernon Pharmaceuticals Provides Update on Its Planned Phase II Clinical Trial
UF startup Algernon Pharmaceuticals Inc., formerly known as Breathtec Biomedical, a clinical-stage pharmaceutical development company, provided an update to the market on... Read More
Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD Studies
Algernon Pharmaceuticals Inc., formerly known as Breathtec, a UF startup, is pleased to report that its lead drugs for non-alcoholic steatohepatitis (NASH)... Read More
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56 Percent
Algernon Pharmaceuticals Inc., formerly known as Breathtec, a UF startup, announced that NP-120, its repurposed lead candidate for the treatment of idiopathic... Read More
Breathtec Announces Name Change to Algernon Pharmaceuticals
UF startup Breathtec Biomedical Inc. is pleased to announce that as a result of the strength of the data from its Nash Pharmaceuticals... Read More
